Lifeboat Foundation

Lex Fridman Podcast full episode: https://www.youtube.com/watch?v=2oHH4aClJQs.
Please support this podcast by checking out our sponsors:
- True Classic Tees: https://trueclassictees.com/lex and use code LEX to get 25% off.
- Audible: https://audible.com/lex to get 30-day free trial.
- InsideTracker: https://insidetracker.com/lex to get 20% off.
- ExpressVPN: https://expressvpn.com/lexpod to get 3 months free.

GUEST BIO:
Noam Brown is a research scientist at FAIR, Meta AI, co-creator of AI that achieved superhuman level performance in games of No-Limit Texas Hold’em and Diplomacy.

Continue reading “AI that learns to negotiate with humans” »

We evaluate davinci-003 across a range of classification, summarization, and generation tasks. Using Scale Spellbook, the platform for large language model apps, we show where davinci-003 significantly outperforms the prior version and where it still has room to improve.

Character is a full stack Artificial General Intelligence (AGI) company.

What if you could create your own AI, and it was always available to help you with anything?

Imagine everything it could do for you, from being your own personal teacher, assistant or even friend. Two months after launching in September, our beta generates 1 billion words per day. Get a glimpse of the future at character.ai.

Tune in at 9:00 a.m. PT / 12:00 p.m. ET on Wed. October 12 when Microsoft CEO Satya Nadella kicks off the comnpany’s Ignite conference.

Never miss a deal again! See CNET’s browser extension 👉 https://bit.ly/39Ub3bv.

Biotech startup Lucy Therapeutics is developing mitochondrial-based small molecule therapies for neurological diseases and recently revealed the first two drugs to emerge from its lead programme targeting Parkinson’s. The company, which takes its name from the 3.2-million-year-old fossil of an ancestor of humankind, presented “promising preclinical data” at the Michael J Fox Foundation’s Parkinson’s Disease Therapeutics Conference in October.

The data shown by Lucy Therapeutics demonstrated that its compounds were able to reverse mitochondrial dysfunctions linked to Parkinson’s. In cellular models of the disease, the drugs boosted levels of cellular energy molecule ATP, prevented the death of neurons, and reduced levels of other hallmarks of Parkinson’s, including a-synuclein.

Longevity. Technology: Mitochondria are widely known as the ‘power generators’ within our cells, and their dysfunction has been linked to a range of age-related diseases. But the role of mitochondria extends beyond cellular energy as they also dictate many of a cell’s key functions. Lucy Therapeutics was founded on the hypothesis that diseases with rate-limiting steps involving mitochondrial dysfunction can potentially be treated by modulating key mitochondrial protein targets. To find out more, we caught up with the company’s founder and CEO, Dr Amy Ripka.

This eye implant engineered from proteins in pig skin can restore sight in people with impaired eyesight as well as the blind.

Biological supramolecular assemblies, such as phospholipid bilayer membranes, have been used to demonstrate signal processing via short-term synaptic plasticity (STP) in the form of paired pulse facilitation and depression, emulating the brain’s efficiency and flexible cognitive capabilities. However, STP memory in lipid bilayers is volatile and cannot be stored or accessed over relevant periods of time, a key requirement for learning. Using droplet interface bilayers (DIBs) composed of lipids, water and hexadecane, and an electrical stimulation training protocol featuring repetitive sinusoidal voltage cycling, we show that DIBs displaying memcapacitive properties can also exhibit persistent synaptic plasticity in the form of long-term potentiation (LTP) associated with capacitive energy storage in the phospholipid bilayer. The time scales for the physical changes associated with the LTP range between minutes and hours, and are substantially longer than previous STP studies, where stored energy dissipated after only a few seconds. STP behavior is the result of reversible changes in bilayer area and thickness. On the other hand, LTP is the result of additional molecular and structural changes to the zwitterionic lipid headgroups and the dielectric properties of the lipid bilayer that result from the buildup of an increasingly asymmetric charge distribution at the bilayer interfaces.

If you fear iMessage spies, iMessage CKV is for you.

Ablation of primary cilia in the striatum did not affect the object recognition memory, as evidenced by the more time mice spent with the novel object than the old object (Fig. 4e, f). Similarly, in the novel location recognition assay, IFT88-KO spent more time with the novel location than the old location (Fig. 4g, h), indicating a normal spatial memory. In addition, the contextual memory, measured using the fear conditioning test, was intact in the IFT88-KO mice, as revealed by the similar freezing time on the test day compared with the control mice (Fig. 4i).

The expression of the immediate-early gene cFos was used as a molecular marker of neural activity. We examined cFos immunoreactivity (number of cFos-positive cells) in structures that are parts of striatal circuits and those known to project to or receive projections from the striatum (Fig. 5a, b). First, the rostral dorsal striatum, but not the caudal striatum of IFT88-KO mice, exhibited a significant decrease of cFos immunoreactivity (Fig. 5c, d). Within the basal ganglia circuit, there was a trend for cFos immunoreactivity reductions in the output regions (SNr and the GPm), but not in the nuclei of the indirect pathway structures (lateral globus pallidus and subthalamic nucleus) (Fig. 5c, d). The main input regions to the striatum include the dopaminergic neurons of the substantia nigra pars compact (SNc) and the glutamatergic neurons of the cortices.